Business Wire

Distributed Technologies Research Simplifies Global Payments

11.12.2024 10:00:00 CET | Business Wire | Press release

Share

Introduces Revolutionary B2B Payment Solutions

Distributed Technologies Research (DTR), a fintech company focused on simplifying global payments infrastructure, officially launched its technology platform today. DTR seamlessly bridges national payment systems around the world to make financial transactions efficient, secure and universally accessible.

Current payment networks suffer from inefficiencies – such as transfer costs, interchange fees, FX conversion charges, settlement delays and other opaque fees – that effectively act as an indirect tax on consumers worldwide. DTR’s innovative solutions mitigate these inequities with an adaptable, compliant and scalable payment systems architecture that is globally accessible to businesses of all sizes.

“Our team has spent several years studying the systemic barriers within traditional payment systems. The amalgamation of national payments systems with blockchain technologies has the potential to eliminate the hidden tax on consumers,” said Akshay Naheta, Founder & CEO of DTR.

DTR has unveiled AmalgamOS™, a state-of-the-art technology stack designed to streamline money transfers and merchant payments. Leveraging its proprietary International Orchestration Network (ION), AmalgamOS™ enhances financial connectivity and security for businesses worldwide. Currently live and trusted by numerous merchants and corporate clients, AmalgamOS™ enables instant fiat-to-fiat, fiat-to-stablecoin and stablecoin-to-fiat transactions in over 40 countries, with a roadmap into more than 100 countries in 2025.

Key Features of AmalgamOS™:

Enhanced Transaction Speed: Transactions settle in minutes, leveraging blockchains’ 24/7 operational capability.

Cost Efficiency: Reduced reliance on intermediaries drastically lowers transaction fees.

Global Reach: Currently operational for payouts in over 40 countries worldwide, with pay-in capabilities available across EU nations. The platform is consistently expanding, with new countries being added monthly to enhance global reach and accessibility.

Developer-Centric Design: Flexible API’s, easy-to-integrate widgets, comprehensive white-label solutions, and a merchant control panel provide extensive optionality through simple integrations.

DTR’s interdisciplinary team combines seasoned professionals from traditional finance, payment systems, blockchains and Web3 technology. “DTR is dedicated to its goal of redefining the payments ecosystem by fostering inclusivity and eliminating inefficiencies, benefitting millions of people worldwide. By leveraging blockchain technologies for transparency, security and instantaneous settlements, DTR is addressing the growing demand for efficient and scalable payments solutions,” said Naheta.

Stablecoin transaction volume reached $8.5 trillion(1) in the second quarter of 2024 alone, and the global cross-border payments market is projected to grow to $290 trillion by 2030 from $190 trillion in 2023(2). DTR is uniquely positioned to lead this global payment systems transformation.

About Distributed Technologies Research (DTR)

Distributed Technologies Research (DTR) is at the forefront of simplifying how businesses conduct secure and seamless money transfers globally. We connect disparate national payment networks to enable a worldwide, instantaneous payments ecosystem. Our proprietary AmalgamOS™ technology and International Orchestration Network (ION) provide next-generation payments infrastructure and solutions.

For more information, visit http://www.dtr.org/

About Akshay Naheta, Founder & CEO, DTR

Akshay Naheta founded DTR with a vision to simplify financial transactions through the creation of an advanced global payments infrastructure. He brings over 20 years of experience in finance and technology, with an intricate understanding of blockchains, financial markets and payment systems. Previously, he held senior executive roles at SoftBank Group, where he spearheaded numerous technology investments in industry leaders such as ARM, Auto1 and Nvidia.

Sources:

(1) a16z, State of Crypto Report 2024. https://tinyurl.com/yn9wwjzj
(2) FTX Intelligence, Cross-border payments market sizing data. https://tinyurl.com/bdr7nkdv

View source version on businesswire.com: https://www.businesswire.com/news/home/20241210988080/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse

Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release

Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye